BMJ:酒精是中青年末期肝病死亡的重要因素

2018-07-25 zhangfan MedSci原创

研究发现,自1999年以来,美国因肝硬化引起的死亡率一直在上升,在酒精性肝硬化风险驱动下,25-34岁人群的死亡风险大幅上升,凸显了民众对肝病预防意识的淡泊

近日研究人员就1999-2016年美国肝病相关死亡变化趋势进行了考察,通过连接点回归法评估肝硬化和肝细胞癌死亡的变化趋势。

1999-2016年间,美国年肝硬化死亡率增加65%,达到34174例,而年肝癌死亡人数为11073例,但曾经肝癌风险较高的亚洲和太平洋裔人群的肝癌死亡率下降了2.7%。肝硬化相关死亡率增加最快的人群为北美印第安人裔,年均增加2.1%。2009-16年间,25-34岁人群肝硬化相关死亡率增加显著,为10.5%,其中酒精摄入以及相关肝病是主导因素。研究期间,肝硬化引起的腹膜炎和脓毒症死亡率大幅上升,分别增加6.1%和7.1%。肝硬化相关死亡率呈现区域差异,仅马里兰州的死亡率下降了1.2%,而肯塔基州增加了6.8%、新墨西哥州增加了6.0%、阿肯色州增加了5.7%、印第安纳州增加了5.0%、阿拉巴马增加了5.0%。肝癌相关死亡率一直呈现出增加的趋势,其中亚利桑那州(5.1%)和堪萨斯州(4.3%)的涨幅最显著。

研究发现,自1999年以来,美国因肝硬化引起的死亡率一直在上升,在酒精性肝硬化风险驱动下,25-34岁人群的死亡风险大幅上升,凸显了民众对肝病预防意识的淡泊。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1848566, encodeId=8c871848566f8, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sun Nov 11 22:28:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334736, encodeId=dd9d334e3627, content=搞研究好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sat Jul 28 15:42:28 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596175, encodeId=40dc15961e5f4, content=<a href='/topic/show?id=6e342260237' target=_blank style='color:#2F92EE;'>#中青年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22602, encryptionId=6e342260237, topicName=中青年)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72b18339957, createdName=xuyu, createdTime=Fri Jul 27 03:28:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334107, encodeId=1a0533410ed3, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Wed Jul 25 15:58:00 CST 2018, time=2018-07-25, status=1, ipAttribution=)]
    2018-11-11 gaoxiaoe
  2. [GetPortalCommentsPageByObjectIdResponse(id=1848566, encodeId=8c871848566f8, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sun Nov 11 22:28:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334736, encodeId=dd9d334e3627, content=搞研究好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sat Jul 28 15:42:28 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596175, encodeId=40dc15961e5f4, content=<a href='/topic/show?id=6e342260237' target=_blank style='color:#2F92EE;'>#中青年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22602, encryptionId=6e342260237, topicName=中青年)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72b18339957, createdName=xuyu, createdTime=Fri Jul 27 03:28:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334107, encodeId=1a0533410ed3, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Wed Jul 25 15:58:00 CST 2018, time=2018-07-25, status=1, ipAttribution=)]
    2018-07-28 thlabcde

    搞研究好资料学习了!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1848566, encodeId=8c871848566f8, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sun Nov 11 22:28:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334736, encodeId=dd9d334e3627, content=搞研究好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sat Jul 28 15:42:28 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596175, encodeId=40dc15961e5f4, content=<a href='/topic/show?id=6e342260237' target=_blank style='color:#2F92EE;'>#中青年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22602, encryptionId=6e342260237, topicName=中青年)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72b18339957, createdName=xuyu, createdTime=Fri Jul 27 03:28:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334107, encodeId=1a0533410ed3, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Wed Jul 25 15:58:00 CST 2018, time=2018-07-25, status=1, ipAttribution=)]
    2018-07-27 xuyu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1848566, encodeId=8c871848566f8, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sun Nov 11 22:28:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334736, encodeId=dd9d334e3627, content=搞研究好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sat Jul 28 15:42:28 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596175, encodeId=40dc15961e5f4, content=<a href='/topic/show?id=6e342260237' target=_blank style='color:#2F92EE;'>#中青年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22602, encryptionId=6e342260237, topicName=中青年)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72b18339957, createdName=xuyu, createdTime=Fri Jul 27 03:28:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334107, encodeId=1a0533410ed3, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Wed Jul 25 15:58:00 CST 2018, time=2018-07-25, status=1, ipAttribution=)]
    2018-07-25 三生有幸9135

    学习一下

    0

相关资讯

新知:首部指南助推肝癌介入治疗规范化

近年来,随着介入医学快速发展与介入微创技术的普及,全国各地越来越多的医院开展经动脉化疗栓塞介入治疗肝细胞癌。为了进一步规范该项介入技术的临床应用,近日在江苏省南京市举办的2018中国医师协会介入医师分会年会上,我国首部《肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南》(简称《指南》)正式发布。

Hepatology:微生物所叶昕研究组在HBV上调的lnc-HUR1调控肝癌发生的机制方面取得进展

随着基因测序技术的发展,越来越多长链非编码RNA(lncRNA)被发现。LncRNA涉及到基因调节的各个方面,包括基因转录,mRNA剪切和核质穿梭等;它们在细胞增殖,分化和细胞凋亡等多种生物过程中发挥重要作用。LncRNA表达异常与多种疾病包括肿瘤的发生密切相关。

Cell Res:CRISPR-Cas9功能基因组学筛查找到癌症靶点

来自荷兰癌症研究所,上海市肿瘤所的研究人员发表了题为“A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma”的研究发现,通过高通量功能基因组学筛查揭示了CDK7可以作为肝癌的潜在治疗靶点。

J Hepatol:饮食和化学诱导的小鼠NASH模型,可快速发展为脂肪性肝炎,纤维化和肝癌

新的小鼠NASH模型在短期内疾病可迅速进展为晚期纤维化和HCC,并模拟了人类NASH的组织学、免疫学和转录特征,这表明它将是临床前药物测试的一个有用的实验工具。

中科院“饿死”癌细胞进展:藏灵芝可抑制肝癌细胞增殖

癌症是世界范围内主要致死疾病之一,它的主要特点是肿瘤细胞不受控制地无限生长,它的快速生长需要大量能量。近年来,科研工作的深入和医学的发展大大提高了肿瘤的诊治效果,从目前医学临床实践来看,有些癌症是可以治愈的。但寻找提高患者愈后的新药也至关重要。电镜下的人体肝癌细胞(图片来源中科院微生物所)科研团队栽培的藏灵芝(图片来源中科院微生物所)“饿死”癌细胞,想法挺好,实现不易而在寻找新药的道路上,早在几十

Gut:中药槐耳颗粒可使肝癌术后复发风险降低26%

我国39家三甲医院共同开展的一项大规模临床试验证实,由药用真菌槐耳制成的中药槐耳颗粒,可显著降低肝癌切除术后患者的复发率,有望填补肝癌缺乏有效辅助疗法的空白。(Gut. 2018 年5月25日在线版 doi: 10.1136/gutjnl-2018-315983)即使是早期肝癌,切除手术后复发率高达40%~70%,没有有效的预防复发的治疗。欧洲肝脏研究学会(EASL)和欧洲癌症治疗研究组织(EOR